Hong Kong Airlines Stock News

SEHK:753
SEHK:753Airlines

Will Air China's Projected 2025 Net Loss Reshape Its Core Narrative (SEHK:753)?

In past guidance for 2025, Air China Limited said it expects to post a net loss of about RMB 1.30 billion to RMB 1.90 billion, with an even larger loss of roughly RMB 1.90 billion to RMB 2.70 billion after excluding non-recurring items. This outlook highlights how underlying operations, once one-off gains and losses are stripped out, could weigh more heavily on Air China’s financial performance. Next, we’ll examine how this projected 2025 loss, particularly after excluding non-recurring...
SEHK:1
SEHK:1Industrials

Is It Too Late To Consider CK Hutchison Holdings (SEHK:1) After A 69% One Year Rally?

If you are wondering whether CK Hutchison Holdings is attractively priced right now or if the recent excitement has already been baked into the share price, this article walks you through that question step by step. The stock recently closed at HK$63.25, with returns of 0.7% over 7 days, 19.5% over 30 days, 17.1% year to date, 69.3% over 1 year, 51.7% over 3 years, and 54.6% over 5 years. This naturally raises questions about how much value is still on the table. These moves are set against...
SEHK:1093
SEHK:1093Pharmaceuticals

What CSPC Pharmaceutical Group (SEHK:1093)'s US$4.7 Billion AstraZeneca Metabolic Deal Means For Shareholders

AstraZeneca recently announced a new collaboration with CSPC Pharmaceutical Group to advance eight next-generation obesity and type 2 diabetes therapies, anchored by CSPC’s AI-driven peptide discovery and once-monthly LiquidGel injection platform, with AstraZeneca receiving worldwide rights outside China to CSPC’s once-monthly injectable weight management portfolio. The agreement includes an upfront payment of US$1.20 billion and up to US$3.50 billion in potential development and regulatory...
SEHK:388
SEHK:388Capital Markets

Will Reduced Losses and Non‑Recurring Gains Change Hong Kong Exchanges and Clearing's (SEHK:388) Narrative

Hong Kong Exchanges and Clearing Limited recently issued earnings guidance for the full year 2025, forecasting net profit attributable to shareholders between RMB 147.99 million and RMB 180.17 million, with profit after excluding non-recurring items expected between RMB 29.19 million and RMB 39.50 million. This guidance points to a significant reduction in prior losses and highlights how non-recurring items still play a meaningful role in the company’s reported profitability. We will now...
SEHK:939
SEHK:939Banks

Global Dividend Stocks To Watch In January 2026

As global markets navigate a volatile start to the year, with U.S. indices experiencing fluctuations due to geopolitical tensions and revised economic forecasts, investors are closely monitoring opportunities in dividend stocks. In such uncertain times, dividend-paying stocks can offer a measure of stability and income potential, making them an attractive option for those seeking to balance growth with consistent returns amidst market turbulence.
SEHK:659
SEHK:659Industrials

A Look At CTF Services (SEHK:659) Valuation After Its New ESG Disclosure Report

CTF Services (SEHK:659) is in focus after its insurance arm, CTF Life, released its first standalone ESG Disclosure Report. The report outlines plans around family wellness, ESG focused investing, and governance and risk management. See our latest analysis for CTF Services. The ESG report lands at a time when momentum in CTF Services' shares has been picking up, with a 1 month share price return of 21.20% and a 1 year total shareholder return of 53.23%. This suggests investors are reacting to...
SEHK:1548
SEHK:1548Life Sciences

GenScript Biotech Links AI Drug Discovery Push With Discounted Valuation

GenScript Biotech (SEHK:1548) recently hosted a major global forum focused on practical applications of artificial intelligence in biopharma and drug discovery. The company is also working with Latent Labs as a wet lab partner to rapidly test and validate AI generated molecules for potential therapeutics. For you as an investor or industry follower, this update highlights how GenScript Biotech is positioning itself at the intersection of AI tools and biopharma research. The company is known...
SEHK:1398
SEHK:1398Banks

Assessing Industrial and Commercial Bank of China (SEHK:1398) Valuation As Renewed Investor Interest Builds

Renewed interest in Industrial and Commercial Bank of China (SEHK:1398) has picked up after-hours, with trading volume in Hong Kong rising alongside supportive economic data that has drawn investors back toward large-cap Chinese banks. See our latest analysis for Industrial and Commercial Bank of China. At a latest share price of HK$6.64, Industrial and Commercial Bank of China has seen a 7.62% 7 day share price return and a 10.30% 90 day share price return. Its 1 year total shareholder...
SEHK:9880
SEHK:9880Machinery

Assessing Ubtech Robotics (SEHK:9880) Valuation After New Intelligent Robotics Partnership Announcement

Why Ubtech Robotics is back on investors’ radar Ubtech Robotics (SEHK:9880) has drawn fresh attention after signing a Partnership Agreement on 22 January 2026 with Liuzhou Industrial Holding Fund and Liuzhou Industrial Guidance Fund to invest across the intelligent robot industry chain. See our latest analysis for Ubtech Robotics. At a latest share price of HK$142.3, Ubtech Robotics has delivered a 30 day share price return of 9.97% and a 1 year total shareholder return of 99.58%. This...